CAR T-Cell Therapy as Second-Line Treatment in LBCL

Video

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

Related Videos
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
James Ignatz-Hoover, MD, PhD
Sundar Jagannath, MBBS
Krina K. Patel, MD, MSc
Olalekan O. Oluwole, MBBS, MD, associate professor, medicine, hematology/oncology, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center
Francesco Di Meo, PhD
Jay Spiegel, MD
Muhamad Alhaj Moustafa, M.D., M.S. of Mayo Clinic
Tatyana Feldman, MD